Polaryx Therapeutics (PLYX) Payables (2024 - 2026)

Polaryx Therapeutics (PLYX) posted quarterly Payables of $850000.0 for Q1 2026, up 80.85% quarter-over-quarter from $470000.0 in Q4 2025.

Polaryx Therapeutics (PLYX) Payables (2024 - 2026) Analysis & Trends

Polaryx Therapeutics (PLYX) has reported Payables for 3 consecutive years, with $850000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Payables changed N/A year-over-year to $850000.0; the TTM figure through Mar 2026 stood at $850000.0 (changed N/A YoY), while the FY2025 annual figure was $470000.0, up 552.78% from the prior year.
Payables climbed to $850000.0 in Q1 2026 per PLYX's latest filing, from $470000.0 in the prior quarter.
Across five years, Payables topped out at $850000.0 in Q1 2026 and bottomed at $72000.0 in Q4 2024.
Historically, Payables has averaged $464000.0 across 3 years, with a median of $470000.0 in 2025.
On a YoY basis, Payables climbed as much as 552.78% in 2025 and fell as far as 552.78% in 2025.
Polaryx Therapeutics' Payables stood at $72000.0 in 2024, then surged by 552.78% to $470000.0 in 2025, then soared by 80.85% to $850000.0 in 2026.
Business Quant data shows PLYX's Payables at $850000.0 in Q1 2026, $470000.0 in Q4 2025, and $72000.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	167.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	470.30 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	108.02 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	428.93 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	35.57 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	622.65 Mn
10	Polaryx Therapeutics	102.35 Mn	90.81 Mn	-	683,000.00

Download Data